Tg Therapeutics (TGTX) Total Liabilities (2010 - 2026)

Tg Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $945.7 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 125.49% year-over-year to $945.7 million; the TTM figure through Mar 2026 stood at $945.7 million (up 125.49% YoY), while the FY2025 annual figure was $415.2 million, up 16.86% from the prior year.
• Total Liabilities was $945.7 million for Q1 2026 at Tg Therapeutics, up from $415.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $945.7 million in Q1 2026 to a low of $117.4 million in Q3 2022.
• Historically, Total Liabilities has averaged $294.3 million across 5 years, with a median of $213.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities declined 5.26% in 2022, then soared 136.84% in 2024.
• A 5-year view of Total Liabilities shows it stood at $135.0 million in 2022, then grew by 25.26% to $169.1 million in 2023, then surged by 110.15% to $355.3 million in 2024, then gained by 16.86% to $415.2 million in 2025, then jumped by 127.75% to $945.7 million in 2026.
• The last three Total Liabilities figures came in at $945.7 million (Q1 2026), $415.2 million (Q4 2025), and $417.8 million (Q3 2025), per Business Quant data.